Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.

Published Date: 04 Mar 2024

After a year in a small prospective trial, 91% of cases had local control.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

2.

Six breast texture patterns linked to higher risk of invasive cancer

3.

Tipiracil hydrochloride and trifluridine tablets are approved by the USFDA for Natco Pharma.

4.

Scientists develop scans that light up aggressive cancer tumors for better treatment

5.

Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot